menu
    • menu
    [{"orgOrder":0,"company":"Cassiopea","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved","graph3":"Cassiopea","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cassiopea \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Cassiopea \/ Not Applicable"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved","graph3":"Cassiopea","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cassiopea \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Cassiopea \/ Cosmo Pharmaceuticals"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Curia","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved","graph3":"Cassiopea","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cassiopea \/ Cassiopea","highestDevelopmentStatusID":"12","companyTruncated":"Cassiopea \/ Cassiopea"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ITALY","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved","graph3":"Cassiopea","amount2":0.23999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0.23999999999999999,"dosageForm":"Topical Cream","sponsorNew":"Cassiopea \/ Sun Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Cassiopea \/ Sun Pharma"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved","graph3":"Cassiopea","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Cassiopea \/ Cassiopea","highestDevelopmentStatusID":"12","companyTruncated":"Cassiopea \/ Cassiopea"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ITALY","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"Androgen receptor","graph1":"Dermatology","graph2":"Approved","graph3":"Cassiopea","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Cassiopea \/ Sun Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Cassiopea \/ Sun Pharma"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ITALY","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Clascoterone","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Cassiopea","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Cassiopea \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Cassiopea \/ Glenmark Pharmaceuticals"},{"orgOrder":0,"company":"Cassiopea","sponsor":"Cosmo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"ITALY","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Clascoterone","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Cassiopea","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Cassiopea \/ Cosmo Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Cassiopea \/ Cosmo Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Cassiopea

    Menu

    Cassiopea

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cassiopea

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Cassiopea

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clascoterone

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Glenmark Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Cosmo and Glenmark Announce the Signing of Distribution and License Agreements for Winlevi® in Europe and Sou...

                            Details : Under the agreements, Glenmark will receive from Cassiopea, the exclusive right to commercialize Winlevi (clascoterone cream), used on the skin (topical) to treat acne vulgaris in people 12 years of age and older, in 15 EU countries as well as in South A...

                            Brand Name : Winlevi

                            Molecule Type : Small molecule

                            Upfront Cash : $5.0 million

                            September 27, 2023

                            Lead Product(s) : Clascoterone

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Glenmark Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cassiopea

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Cassiopea

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clascoterone

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Sun Pharmaceutical Industries Limited

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Cosmo and Sun Pharma Announce Territory Expansion of License and Supply Agreements for WINLEVI® to include Ja...

                            Details : Under the terms of the above referred agreements, Sun Pharma will receive from Cassiopea the exclusive right to develop and commercialize WINLEVI (clascoterone) in Japan, Australia, New Zealand, Brazil, Mexico and Russia.

                            Brand Name : Winlevi

                            Molecule Type : Small molecule

                            Upfront Cash : $7.0 million

                            July 25, 2022

                            Lead Product(s) : Clascoterone

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Sun Pharmaceutical Industries Limited

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cassiopea

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Cassiopea

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clascoterone

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Recipient : Sun Pharmaceutical Industries Limited

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sun Pharma Presents Phase 3 Data for WINLEVI® (clascoterone) cream 1% for the Topical Treatment of Acne Vulga...

                            Details : Results from two pivotal clinical trials of WINLEVI (clascoterone) cream 1% for the topical treatment of acne vulgaris (acne)showed favorable safety and efficacy data for WINLEVI in patients with acne aged 12 years and older.

                            Brand Name : Winlevi

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 25, 2022

                            Lead Product(s) : Clascoterone

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Recipient : Sun Pharmaceutical Industries Limited

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Cassiopea

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Cassiopea

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clascoterone

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Cosmo Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Cosmo Pharmaceuticals N.V. Launches Public Exchange Offer to Acquire Cassiopea S.p.A.

                            Details : Through the acquisition, Cosmo will leverage the Cassiopea and advance the development of its R&D pipeline, including Winlevi (clascoterone), which is indicated for acne vulgaris.

                            Brand Name : Winlevi

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 04, 2021

                            Lead Product(s) : Clascoterone

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Cosmo Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Cassiopea

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Cassiopea

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clascoterone

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Sun Pharmaceutical Industries Limited

                            Deal Size : $235.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Sun Pharma, Cassiopea Signing of License and Supply Agreements for Winlevi®

                            Details : Under the terms of the above referred agreements, Sun Pharma will have the exclusive right to commercialize Winlevi® in the United States and Canada, and Cassiopea will be the exclusive supplier of the product.

                            Brand Name : Winlevi

                            Molecule Type : Small molecule

                            Upfront Cash : $45.0 million

                            July 26, 2021

                            Lead Product(s) : Clascoterone

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Sun Pharmaceutical Industries Limited

                            Deal Size : $235.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Cassiopea

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Cassiopea

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clascoterone

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Recipient : Curia

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Curia Named Exclusive API Supplier for Recently Approved Acne Treatment

                            Details : Curia has been named as the exclusive supplier of the active pharmaceutical ingredient (API) in Cassiopea SpA’s (SIX: SKIN) recently approved acne treatment, Winlevi® (clascoterone) cream 1%.

                            Brand Name : Winlevi

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 30, 2020

                            Lead Product(s) : Clascoterone

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Recipient : Curia

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Cassiopea

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Cassiopea

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clascoterone

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Cosmo Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cassiopea Receives FDA Approval for Winlevi® (clascoterone Cream 1%)

                            Details : Winlevi (clascoterone cream 1%) is approved for the treatment of acne vulgaris in people aged 12 and older. In pivotal clinical trials, WINLEVI demonstrated treatment success and reductions in acne lesions and was well tolerated when used twice a day.

                            Brand Name : Winlevi

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 27, 2020

                            Lead Product(s) : Clascoterone

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Cosmo Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Cassiopea

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Cassiopea

                            Italy arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Clascoterone

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Cassiopea Announces JAAD Publication of Positive Results from A Long-Term Safety Study of Clascoterone Cream 1...

                            Details : The study demonstrated that Clascoterone cream 1%, has favorable long-term safety for the treatment of acne with low rates of treatment related adverse events (AEs).

                            Brand Name : CB-03-01

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 23, 2020

                            Lead Product(s) : Clascoterone

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth